Avantax Advisory Services Inc. Makes New $1.22 Million Investment in Aligos Therapeutics, Inc. (NASDAQ:ALGS)

Avantax Advisory Services Inc. purchased a new stake in Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 30,570 shares of the company's stock, valued at approximately $1,218,000. Avantax Advisory Services Inc. owned 0.85% of Aligos Therapeutics as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. AlphaMark Advisors LLC raised its stake in shares of Aligos Therapeutics by 1,000.0% in the 4th quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company's stock valued at $44,000 after acquiring an additional 1,000 shares during the period. Golden State Wealth Management LLC purchased a new stake in shares of Aligos Therapeutics in the 4th quarter valued at approximately $107,000. Charles Schwab Investment Management Inc. raised its stake in shares of Aligos Therapeutics by 19.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 14,286 shares of the company's stock valued at $569,000 after acquiring an additional 2,306 shares during the period. Finally, Drive Wealth Management LLC purchased a new stake in shares of Aligos Therapeutics in the 4th quarter valued at approximately $916,000. 60.43% of the stock is owned by hedge funds and other institutional investors.

Aligos Therapeutics Price Performance

Shares of ALGS stock traded down $0.77 during trading on Friday, reaching $10.75. The company's stock had a trading volume of 96,622 shares, compared to its average volume of 172,260. The company has a market capitalization of $65.73 million, a price-to-earnings ratio of -0.81 and a beta of 2.52. The stock's 50-day moving average price is $21.44 and its 200 day moving average price is $20.32. Aligos Therapeutics, Inc. has a 1-year low of $6.76 and a 1-year high of $46.80.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last announced its quarterly earnings data on Monday, March 10th. The company reported ($13.08) earnings per share for the quarter, missing analysts' consensus estimates of ($2.63) by ($10.45). The business had revenue of $0.63 million during the quarter, compared to analyst estimates of $0.43 million. Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. During the same quarter last year, the firm posted ($5.50) EPS. On average, sell-side analysts anticipate that Aligos Therapeutics, Inc. will post -10.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reduced their price target on shares of Aligos Therapeutics from $75.00 to $70.00 and set a "buy" rating on the stock in a research note on Tuesday, March 11th.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).